论文部分内容阅读
事件回顾: 4月22日、24日广东某医院重症肝炎病人中先后出现2例急性肾功能衰竭症状。4月29日、30日出现多例相同症状病人,紧急组织肝肾病专家会诊,怀疑可能是齐二药公司生产的亮菌甲素注射液引起。5月1日医院停止使用该药。5月2日晚上报省卫生厅和省药品不良反应检测中心。5月3日广东省食品药品监督管理局和卫生厅采取相关措施。5月12日国家食品药品监督管理局发出紧急通知,在全国范围内停止销售和使用齐齐哈尔第二制药有限公司生产的所以药品,同时要求各地药监部门在本辖区内就地查封、扣押。截至到目前为止,已确定齐齐哈尔第二制药有限公司生产的“亮菌甲素”假药造成的死亡人数有9人。
Event Review: April 22, 24 in Guangdong hospital severe hepatitis patients have 2 cases of acute renal failure symptoms. April 29, 30 cases of multiple patients with the same symptoms, emergency liver and kidney disease specialist consultation, suspected may be Qi Er medicine company produced by strychnine injection caused. May 1 hospital to stop using the drug. May 2 evening provincial health department and the provincial center for adverse drug reactions testing. May 3 Guangdong Food and Drug Administration and the Department of Health to take relevant measures. On May 12, the SFDA issued an urgent circular to stop the sale and use of all medicines manufactured by Qiqihaer Second Pharmaceutical Co., Ltd. throughout the country. At the same time, it urged drug administrations across the country to seize and seize in place in their jurisdictions. Up to now, it has been determined that there are 9 deaths caused by the “strychnine” counterfeit medicines manufactured by Qiqihar Pharmaceutical Co., Ltd.